secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116348
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome completes Morphimmune merger, $125M PIPE, Q3 net loss $4M
------------------------------------------------------------------

- Completed merger with Morphimmune; concurrent $125M oversubscribed PIPE from Enavate Sciences, EcoR1 Capital, Redmile, Janus Henderson, Avidity, Woodline.
- Clay B. Siegall (ex-Seagen CEO) appointed Chairman & CEO; Bob Lechleider as CMO; Jean-Jacques Bienaimé (ex-BioMarin CEO) to board.
- Q3 collaboration revenue $4M from AbbVie; R&D and G&A each $4M; net loss $4M ($0.36 per share); cash $91M as of Sept 30.
- Cash runway extended into Q1 2026; expect IMM-ONC-01 IND guidance Q1 2024; 177Lu-FAP IND submission Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/0001104659-23-116348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/tm2330142d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer